Vertex Pharmaceutic (VRTX) Stock Price, Quote & News

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 341 6100

Website: www.vrtx.com

Address:

50 Northern Avenue, Boston, United States

akinyo Sep. 11 at 5:44 PM

$VRTX Big day! big move!

0 · Reply

DimondTrade100 Sep. 10 at 2:55 PM

$VRTX The investment case is a call option on the success of its non-CF therapies to diversify away from the eventual saturation of its triplett franchise.

0 · Reply

NVDAMillionaire Sep. 10 at 12:59 PM

$VRTX Brilliant piece that captures VRTX's situation perfectly. So if you want to update your understanding of VRTX or get to know VRTX better, this is essential reading. https://beyondspx.com/quote/VRTX/analysis/vertex-pharmaceuticals-launching-a-new-era-of-growth-and-diversification-vrtx

1 · Reply

SuperGreenToday Sep. 10 at 6:37 AM

$VRTX The moat around its CF franchise is deep, but the future depends on the success of non-CF programs like Casgevy to diversify away from a single therapy.

0 · Reply

AAUS1 Sep. 10 at 6:05 AM

$VRTX deserves much higher valuation ? Will the big boys eye it ?

0 · Reply

THE_Monkey_Banana_Genius Sep. 9 at 5:59 PM

$ALNY $ARGX $MDGL $VRTX damn. Too bad i was a 🦐 biscuit and got shaken out. Lame

1 · Reply

geroscience Sep. 9 at 10:19 AM

$LCTX With today's PR Culley seems to be throwing down the gauntlet at $VRTX Vertex's Viacyte and saying: We think we will be able to manufacture pancreatic islet cells for type 1 diabetes at scale in a GMP-compliant manner - and you can't. For context, Vertex leads in the T1DM islet cell replacement space with an ongoing pivotal Ph3 trial in n=50 Pxs (yes - you can run pivotal trials with a sample size of 50 when your treatment's efficacy is transformative...reminiscent of OpRegen). Thus far their data in n=12 Pxs is looking like a "functional cure" for T1DM (ignoring immunosuppression). Vertex is also to my knowledge the largest pure biotech by marketcap at $101B. This is a bold proclamation from Culley - let's see how it plays out... https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes

2 · Reply

svertical1 Sep. 8 at 7:01 PM

$VRTX So Vertex needs to price better! I really tried to get Journavx, but Surgeon, anesthesiologist, nurses all said Journavx is too expensive. After 3 days of constipation from Oxy’s, and totally understanding the concept of how when the solar system finally collapses it will eventually be the size of one of my turds, Vertex should not give them such an easy excuse.

3 · Reply

kamenrider888 Sep. 6 at 11:02 AM

$VRTX where are all the bulls and bots who said this was going to $600 LMAO

0 · Reply

JoeB07 Sep. 6 at 8:41 AM

$VRTX and $UTHR ... $INSM is coming for your markets. INSM has better drugs. Period. Love both of your companies, but keep your eye on the prize. Have fun.

0 · Reply

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Sep 9, 2025, 2:01 PM EDT - 2 days ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 1:47 PM EDT - 3 days ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST

Sep 3, 2025, 3:57 PM EDT - 8 days ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 2, 2025, 9:00 AM EDT - 9 days ago

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

Aug 20, 2025, 4:00 PM EDT - 22 days ago

Vertex to Participate in Upcoming September Investor Conferences

Aug 18, 2025, 9:01 AM EDT - 24 days ago

Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More

ADBE

Aug 12, 2025, 2:34 PM EDT - 4 weeks ago

Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet

Aug 11, 2025, 4:47 PM EDT - 4 weeks ago

Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)

Aug 5, 2025, 2:05 PM EDT - 5 weeks ago

Weakness In Vertex Stock Seen As Buying Opportunity

Aug 5, 2025, 1:58 PM EDT - 5 weeks ago

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Aug 5, 2025, 10:25 AM EDT - 5 weeks ago

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Aug 5, 2025, 8:09 AM EDT - 5 weeks ago

Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

ICHR INSP

Aug 4, 2025, 8:13 PM EDT - 5 weeks ago

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 5:40 PM EDT - 5 weeks ago

Vertex tops estimates on cystic fibrosis treatment strength, new products

Aug 4, 2025, 5:13 PM EDT - 5 weeks ago

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger Earnings

Aug 4, 2025, 4:59 PM EDT - 5 weeks ago

Vertex Pharmaceuticals reports earnings, beating EPS, revenue estimates

Aug 4, 2025, 4:24 PM EDT - 5 weeks ago

Vertex to stop developing new painkiller as solo treatment after mid-stage study setback

Aug 4, 2025, 4:01 PM EDT - 5 weeks ago

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain

Aug 4, 2025, 4:01 PM EDT - 5 weeks ago

Vertex Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 1:48 PM EDT - 5 weeks ago

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Aug 2, 2025, 12:20 AM EDT - 5 weeks ago

How Will VRTX Stock React To Its Upcoming Earnings?

Aug 1, 2025, 8:31 AM EDT - 5 weeks ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 5 weeks ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 9:52 AM EDT - 6 weeks ago

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

BSX CAH DXCM EW ISRG LLY PODD

Jul 14, 2025, 7:01 PM EDT - 2 months ago

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Jul 14, 2025, 8:30 AM EDT - 2 months ago

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

Jul 9, 2025, 3:09 PM EDT - 2 months ago

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch

Jul 8, 2025, 4:00 PM EDT - 2 months ago

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

Jul 8, 2025, 10:41 AM EDT - 2 months ago

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

BMY GILD JNJ NVO PFE

Jul 1, 2025, 7:46 AM EDT - 2 months ago

Vertex's next-generation cystic fibrosis drug gets EU approval

Jul 1, 2025, 7:34 AM EDT - 2 months ago

Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis

Jun 23, 2025, 4:00 AM EDT - 2 months ago

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

Jun 22, 2025, 8:32 PM EDT - 2 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript

Jun 20, 2025, 7:15 PM EDT - 2 months ago

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

Jun 10, 2025, 6:07 PM EDT - 3 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 6, 2025, 12:00 PM EDT - 3 months ago

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

May 30, 2025, 11:01 AM EDT - 3 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

May 23, 2025, 9:46 AM EDT - 3 months ago

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?

May 15, 2025, 4:05 PM EDT - 4 months ago

Vertex to Participate in Upcoming Investor Conferences

May 9, 2025, 1:38 PM EDT - 4 months ago

Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft

MSFT PLTR WYNN

May 6, 2025, 10:12 PM EDT - 4 months ago

Vertex On Track To Significantly Improve Revenue And Earnings By 2030

May 6, 2025, 4:28 PM EDT - 4 months ago

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

May 6, 2025, 12:31 PM EDT - 4 months ago

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why.

May 6, 2025, 12:06 PM EDT - 4 months ago

Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More

CEG DASH

May 6, 2025, 8:08 AM EDT - 4 months ago

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

FN ICHR

May 6, 2025, 8:04 AM EDT - 4 months ago

Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)

May 5, 2025, 8:01 PM EDT - 4 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:18 PM EDT - 4 months ago

Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug

May 5, 2025, 4:01 PM EDT - 4 months ago

Vertex Reports First Quarter 2025 Financial Results

akinyo Sep. 11 at 5:44 PM

$VRTX Big day! big move!

0 · Reply

DimondTrade100 Sep. 10 at 2:55 PM

$VRTX The investment case is a call option on the success of its non-CF therapies to diversify away from the eventual saturation of its triplett franchise.

0 · Reply

NVDAMillionaire Sep. 10 at 12:59 PM

1 · Reply

SuperGreenToday Sep. 10 at 6:37 AM

$VRTX The moat around its CF franchise is deep, but the future depends on the success of non-CF programs like Casgevy to diversify away from a single therapy.

0 · Reply

AAUS1 Sep. 10 at 6:05 AM

$VRTX deserves much higher valuation ? Will the big boys eye it ?

0 · Reply

THE_Monkey_Banana_Genius Sep. 9 at 5:59 PM

$ALNY $ARGX $MDGL $VRTX damn. Too bad i was a 🦐 biscuit and got shaken out. Lame

1 · Reply

geroscience Sep. 9 at 10:19 AM

2 · Reply

svertical1 Sep. 8 at 7:01 PM

3 · Reply

kamenrider888 Sep. 6 at 11:02 AM

$VRTX where are all the bulls and bots who said this was going to $600 LMAO

0 · Reply

JoeB07 Sep. 6 at 8:41 AM

$VRTX and $UTHR ... $INSM is coming for your markets. INSM has better drugs. Period. Love both of your companies, but keep your eye on the prize. Have fun.

0 · Reply

JoeB07 Sep. 6 at 8:32 AM

$VRTX everyone here is bottom fishing. You want some growth, like where VRTX was years ago, then buy some INSM. It's going to be epic. I always tag this board because I feel sorry for you and the CEO that has been squandering your investment for years. INSM has a clear vision and it's paying out daily in benjamins. VRTX could have bought INSM a couple years back on the cheap and your CEO was an idiot who thought she could drug pick, instead of investing in real results. I predict that INSM will someday buy VRTX on the cheap. We shall see.

0 · Reply

svertical1 Sep. 5 at 9:55 PM

$VRTX So value company with leading therapies for •CF •SCD/TDT •Acute Pain •Diabetes •Kidney •Autoimmune Disease

2 · Reply

theDIOyears Sep. 5 at 5:22 PM

$VRTX The results of this small, short-term study involving persons with type 1 diabetes support the hypothesis that zimislecel can restore physiologic islet function, warranting further clinical investigation. https://www.nejm.org/doi/full/10.1056/NEJMoa2506549

0 · Reply

JoeB07 Sep. 5 at 1:26 PM

$INSM so you're saying there's a chance.... going to be a big day today. $MRK $VRTX $AZN

1 · Reply

cuttail07 Sep. 5 at 12:33 PM

$VRTX

1 · Reply

svertical1 Sep. 5 at 4:50 AM

$VRTX Hospital (major orthopedic hospital) pharmacy does not have access to Journavx but complimented Vertex Reps for promoting. Said it’s too ‘expensive’. Said more patients are requesting Journavx. They’ll fall in line, but also implied Ins Co won’t pay…..doubtful?

1 · Reply

Quantumup Sep. 4 at 3:37 PM

H.C. Wainwright y'day reiterated $TVTX Buy/$47. $SYBX $NVS $AHKSY $VRTX #ICIEM25 H.C. Wainwright said that in finds the long-term HCU data presented at the Int'l Congress of Inborn Errors of Metabolism as 'Highly Encouraging' w/ 'Clinically Meaningful Reductions in Key Metabolites Sustained Over Approximately One Year of Treatment with Pegtibatinase.' H.C. Wainwright said in its note to investors:

0 · Reply

svertical1 Sep. 4 at 2:25 PM

$VRTX Big gaps remain, both at $450 & $500!

0 · Reply

svertical1 Sep. 4 at 1:31 PM

$VRTX Going in for shoulder surgery today, and ask to try Journavx. Doc said he was recently at conference where several surgeons mentioned they have started using it with success. I’ll report back my experience in a few days.

0 · Reply

cuttail07 Sep. 4 at 12:34 PM

$VRTX that was a great webcast yesterday. Good questions by the interviewer on the NaV inhibitor clinical trials (withdrawal of VX-993 in acute pain and canceling p3 LSR in favor of another DPN trial as anchor indication in peripheral neuropathy).

1 · Reply

muskegbaymomentum Sep. 4 at 12:18 AM

$VRTX seems like a deal.

0 · Reply

scientificway Sep. 3 at 3:40 PM

$VRTX strong buy. PMN, Have cash and good result. Should be 0.5-13 gain to loss ratio is very high

0 · Reply

Market Cap	99.62B
Revenue (ttm)	11.02B
Net Income (ttm)	-535.60M
EPS (ttm)	N/A
PE Ratio	26.20
Forward PE	24.97
Profit Margin	-4.86%
Debt to Equity Ratio	0.00

Volume	1,330,100
Avg Vol	1,721,526
Day's Range	N/A - N/A
Shares Out	256.39M
Stochastic %K	65%
Beta	0.44
Analysts	Sell
Price Target	$488.77